A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice-Reference-Cited by-同舟云学术

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice

Published:2023-04-01 Issue:4 Volume:30 Page:326-334
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Munkhjargal Uugantsetseg¹,Fukuda Daiju¹,Ganbaatar Byambasuren¹,Suto Kumiko¹,Matsuura Tomomi¹,Ise Takayuki¹,Kusunose Kenya¹,Yamaguchi Koji¹,Yagi Shusuke¹,Yamada Hirotsugu²,Soeki Takeshi³,Wakatsuki Tetsuzo¹,Sata Masataka¹

Affiliation:

1. Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences

2. Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences

3. Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/30/4/30_63382/_pdf

Reference49 articles.

1. 1) Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB and Tsao CW. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation, 2020; 141: e139-e596

2. 2) Fuller PJ and Young MJ. Mechanisms of mineralocorticoid action. Hypertension, 2005; 46: 1227-1235

3. 3) Pascual-Le Tallec L and Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol, 2005; 19: 2211-2221

4. 4) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999; 341: 709-717

5. 5) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ and Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex;Journal of the American Heart Association;2024-09-09

2. Esaxerenone Attenuates Aldosterone-Induced Mitochondrial Damage-Mediated Pyroptosis in Mouse Aorta and Rat Vascular Smooth Muscle Cells;Life;2024-07-31

3. Additive Effects of Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker, on Cardioplegic Arrest in Rat Hearts;Annals of Thoracic and Cardiovascular Surgery;2024

4. Fenugreek extract improves diabetes-induced endothelial dysfunction via the arginase 1 pathway;Food & Function;2024

5. Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway;Biomedicines;2023-12-15